What other stocks do shareholders of Kadmon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kadmon investors own include Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Organigram (OGI) , KushCo (KSHB) , Gran Tierra Energy (GTE) , Zosano Pharma (ZSAN) , Bionano Genomics (BNGO) , Pennsylvania Real Estate Investment Trust (PEI) , Auxly Cannabis Group (CBWTF) and CNBX Pharmaceuticals (CNBX) .

Kadmon (KDMN) raised $101 million in an initial public offering (IPO) on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

NYSE:KDMN

Kadmon (KDMN) Stock Price, News & Analysis

→ Uncover this 2024 Hidden Gem (From Tips4Traders) (Ad)

Free KDMN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $9.50
▼
$9.50
50-Day Range: $9.50
▼
$9.50
52-Week Range: $3.19
▼
$9.50

Volume: 1,052 shs
Average Volume: 5.11 million shs
Market Capitalization: $1.70 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Kadmon alerts:

Ad Darwin

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your crypto report

About Kadmon Stock (NYSE:KDMN)

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Ad Darwin

2024's Must-Have Guide: Master Crypto Investment Today

Click here to download your crypto report

KDMN Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive KDMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kadmon and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Sub-Industry: N/A
Current Symbol: NYSE:KDMN
CUSIP: N/A
CIK: N/A
Web: N/A
Phone: 12123086000
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 178,521,000
Free Float: N/A
Market Cap: $1.70 billion
Optionable: Optionable
Beta: N/A

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Competitors

View All Competitors

KDMN Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Kadmon own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kadmon investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Organigram (OGI), KushCo (KSHB), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Auxly Cannabis Group (CBWTF) and CNBX Pharmaceuticals (CNBX).
When did Kadmon IPO?: Kadmon (KDMN) raised $101 million in an initial public offering (IPO) on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

This page (NYSE:KDMN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kadmon (KDMN) Stock Price, News & Analysis

About Kadmon Stock (NYSE:KDMN)

KDMN Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Competitors

KDMN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info